Pembrolizumab regimen extends survival in advanced esophageal cancer

The addition of pembrolizumab to first-line chemotherapy extended OS and PFS among patients with locally advanced or metastatic esophageal cancer, according to the agent’s manufacturer.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *